DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial.

Author(s): Mataix-Cols D(1), Turner C, Monzani B, Isomura K, Murphy C, Krebs G, Heyman I.

Affiliation(s): Author information: (1)David Mataix-Cols, PhD, Cynthia Turner, PhD, Benedetta Monzani, MSc, Kayoko Isomura, MD, PhD, Caroline Murphy, MSc, Georgina Krebs, DClinPsych, Isobel Heyman, MBBS, PhD, FRCPsych, King's College London, Institute of Psychiatry and OCD and Related Disorder Clinic for Young People, South London and Maudsley NHS Foundation Trust, London, UK.

Publication date & source: 2014, Br J Psychiatry. , 204(1):77-8

A partial N-methyl-D-aspartate agonist, D-cycloserine, enhances fear extinction when given before or shortly after exposure to feared stimuli in animals. In this pilot double-blind placebo-controlled trial (trial number: ISRCTN70977225), 27 youth with obsessive-compulsive disorder were randomised to either 50 mg D-cycloserine or placebo administered immediately after each of ten cognitive-behavioural therapy (CBT) sessions, primarily consisting of exposure and ritual prevention. Both groups improved significantly and maintained their gains at 1-year follow-up, with no significant advantage of D-cycloserine over placebo at any time point. The effects of CBT may not be augmented or accelerated when D-cycloserine is administered after sessions.

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017